LTGOLatigo Biotherapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Latigo Biotherapeutics, Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LTGO본 종목 | $1.6B#1 | — | — | — | — | — | — | — | — | — | — | — |
| NNVC | $30M#2 | — | 3.2x#10 | — | — | -14.1%#12 | — | -103.4%#6 | -89.9%#5 | — | -5.5%#4 | — |
| HEPA | $29M#3 | — | 22.4x#13 | — | — | 37.3%#6 | — | -647.5%#12 | — | — | -17.6%#7 | — |
| APUS | $3M#16 | — | 0.0x#1 | — | — | -331.7%#15 | — | -5.6%#2 | -11.2%#2 | — | -89.4%#14 | — |
| IGC | $28M#4 | — | 4.6x#11 | 22.2x#7 | -5.5%#4 | 45.2%#4 | -585.8%#7 | -116.1%#7 | -125.5%#6 | 3#3 | -33.7%#8 | — |
| NXTC | $28M#5 | — | 2.3x#7 | 1.3x#2 | 252.6%#1 | -0.3%#10 | -257.5%#3 | -459.7%#11 | — | — | 7.9%#3 | — |
| TXMD | $25M#6 | — | 0.9x#5 | 8.4x#5 | 71.6%#2 | 73.9%#1 | -145.3%#2 | -2.1%#1 | -3.8%#1 | 5#1 | 93.8%#1 | — |
| ATOS | $25M#7 | — | 0.9x#4 | 13992.6x#8 | -95.6%#8 | -36.3%#13 | -2112684.9%#8 | -129.6%#8 | — | — | -79.9%#12 | — |
| ACTU | $24M#8 | — | 24.3x#14 | — | — | 18.5%#7 | — | -2247.2%#14 | — | — | -85.6%#13 | — |
| LTRN | $23M#9 | — | — | — | — | 17.6%#8 | — | — | — | — | -54.6%#10 | — |
| CLRB | $23M#10 | — | 0.8x#3 | — | — | 51.1%#2 | — | -72.9%#4 | — | — | -54.7%#11 | — |
| TVRD | $23M#11 | — | 2.7x#9 | 3.2x#3 | -66.0%#6 | 38.1%#5 | -374.8%#5 | -217.3%#10 | — | — | -95.6%#15 | — |
| COCP | $21M#12 | — | 20.6x#12 | 10.7x#6 | -69.3%#7 | 49.5%#3 | -447.8%#6 | -845.9%#13 | -20.4%#3 | 3#3 | -15.2%#5 | — |
| AYTU | $21M#13 | — | 0.6x#2 | 0.3x#1 | 1.8%#3 | 14.4%#9 | -11.8%#1 | -38.6%#3 | -41.4%#4 | 4#2 | -15.7%#6 | — |
| RKTO | $20M#14 | — | 2.4x#8 | — | — | -52.3%#14 | — | -152.0%#9 | — | — | -53.7%#9 | — |
| MRKR | $20M#15 | — | 1.6x#6 | 5.5x#4 | -46.2%#5 | -13.3%#11 | -363.5%#4 | -100.0%#5 | -1413.6%#7 | — | 18.6%#2 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice